Immediate Impact

2 by Nobel laureates 2 from Science/Nature 66 standout
Sub-graph 1 of 22

Citing Papers

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
3 intermediate papers

Works of Anjali Vaze being referenced

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
2020
and 2 more

Author Peers

Author Last Decade Papers Cites
Anjali Vaze 151 92 25 109 14 313
C.E. Newman 152 122 19 88 18 366
Farzana L. Walcott 128 24 11 122 17 283
Margit Stimpfl 104 26 28 188 16 363
Hans Strauß 83 21 17 59 12 268
Craig Vargo 169 37 28 113 20 333
L Anselmi 183 36 23 84 17 346
M. Zahurak 81 13 25 177 11 364
J P Guastalla 216 84 17 72 15 318
Liliane Morel-Maroger Striker 81 30 90 177 9 352
Yan Li 106 20 6 134 19 347

All Works

Loading papers...

Rankless by CCL
2026